BNP Paribas Financial Markets
NVCT icon

BNP Paribas Financial Markets’s Nuvectis Pharma NVCT Stock Holding History

BNP Paribas Financial Markets’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.4K Buy
3,542
+1
+0% +$9 ﹤0.01% 4982
2025
Q4 		$26.7K Buy
3,541
+743
+27% +$4.84K ﹤0.01% 4938
2025
Q3 		$16.8K Buy
2,798
+1,652
+144% +$11.4K ﹤0.01% 4930
2025
Q2 		$8.56K Buy
1,146
+1,044
+1,024% +$9.47K ﹤0.01% 4875
2025
Q1 		$997 Sell
102
-13
-11% -$94 ﹤0.01% 5071
2024
Q4 		$622 Buy
+115
New +$720 ﹤0.01% 5145

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BNP Paribas Financial Markets's NVCT Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Nuvectis Pharma (NVCT) stake by 0.03% in Q1 2026, buying an estimated $9 and bringing the position to 3,542 shares worth $27.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4982.

BNP Paribas Financial Markets first reported a position in NVCT in Q4 2024 and has held it in 6 quarters since. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • BNP Paribas Financial Markets held 3,542 shares of Nuvectis Pharma worth $27.4K as of Q1 2026.
  • BNP Paribas Financial Markets bought 1 Nuvectis Pharma share in Q1 2026, an estimated $9.
  • Nuvectis Pharma made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4982 holding.
  • BNP Paribas Financial Markets first reported a position in Nuvectis Pharma in Q4 2024 and has held it in 6 quarters since.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.